Oncology Pharma (OTCMKTS:ONPH) vs. Rafael (NYSE:RFL) Critical Analysis

Rafael (NYSE:RFL) and Oncology Pharma (OTCMKTS:ONPH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, profitability and risk.

Volatility & Risk

Rafael has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Comparatively, Oncology Pharma has a beta of -4.93, indicating that its stock price is 593% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Rafael and Oncology Pharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rafael	1	0	0	0	1.00
Oncology Pharma	0	0	0	0	0.00

Earnings & Valuation

This table compares Rafael and Oncology Pharma”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rafael	$920,000.00	119.26	-$30.52 million	($0.68)	-3.10
Oncology Pharma	N/A	N/A	N/A	N/A	N/A

Oncology Pharma has lower revenue, but higher earnings than Rafael.

Profitability

This table compares Rafael and Oncology Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rafael	-3,321.74%	-41.27%	-35.32%
Oncology Pharma	N/A	N/A	N/A

Insider & Institutional Ownership

11.3% of Rafael shares are held by institutional investors. 32.9% of Rafael shares are held by insiders. Comparatively, 18.0% of Oncology Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Rafael beats Oncology Pharma on 5 of the 8 factors compared between the two stocks.

About Rafael

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

About Oncology Pharma

Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated in 1993 and is based in San Francisco, California.